GenE-HumDi experts have elaborated a white paper to introduce the use of genome editing to not technological audiences. Our purpose is to share how this new technology can help correct certain genetic defects causing disease and to engage not only Genetic specialist but as many EU citizens as possible to promote making todays lines of research into actual gene medicines.
Author: Fco. Javier Molina Estévez
The COST Action CA21113: Genome editing for the treatment of Human Disease is a network committed fostering young talent in the genome editing field and thus organized several Training Schools in 2026 to reach most topics and prospective young researchers all over Europe.
Our most recent COST Action Training School, “PRIME EDITING IN PRACTICE: From Design to Application”, has successfully concluded, marking a significant milestone for the European genomics community. Hosted as part of the ongoing initiative to foster advanced genetic research (details available in previous post), the event took place at Ciemat ( Madrid, Spain) and brought together a dynamic group of international experts and emerging researchers. The Excellence of this Training School was sanctioned by the support of Spanish Advanced Therapies Network ( Red TeRav+) and the Spanish Society of Gene and Cell Therapy (SETGyC).
Prime editing is rapidly emerging as a highly promising and precise genome editing tool, offering unprecedented potential for correcting the genetic mutations responsible for inherited diseases. To ensure Europe remains at the forefront of this critical medical frontier, the training school focused heavily on translating this theoretical promise into practical laboratory skills.
The intensive training program featured 10 distinguished international trainers who provided hands-on instruction and mentorship to 17 trainees selected from across Europe. The participants gained critical, cutting-edge genome editing skills and established vital networking connections that will warrant and drive the future of genome editing collaborations throughout Europe.
Majority of trainees were granted support from European GenE-HumDi COST Action, but also Spanish SETGyC and Red TerAv+ contributed to pave a brighter future your young Genome eEditing Talents.
The comprehensive Prime Editing in practice two-day curriculum bridged the gap between theoretical knowledge and laboratory execution. The schedule immersed trainees in the complete prime editing workflow:
- Tuesday, July 1st: Participants opened the school with a comprehensive prime editing overview. This was immediately followed by a practical session covering PEmax mRNA in vitro transcription, alongside a workshop dedicated to guide design tools. Following the lunch break, the trainers led an afternoon practical session on RNA purification and further practical work in guide design.
- Wednesday, July 2nd: The second day expanded into broader medical use cases with two dedicated sessions on prime editing applications. After the lunch break, trainees applied their knowledge in a highly technical practical session on PE nucleofection, utilizing PE mRNA and guides. The technical training concluded with a practical session on CRISPResso analysis to verify editing outcomes.
Beyond the exceptional technical instruction, the trainees and trainers established vital networking connections that will drive collaborative research. By equipping these 17 European trainees with direct experience and invaluable expert contacts, the COST Action has helped to warrant a bright, collaborative future for genome editing therapies in Europe.
Participants of the GenE-HumDi Training School: Prime Editing in Practice: From Design to Application, posing during a course break
For more information about the training school and future COST Action events, please visit https://www.genehumdi.eu/prime-editing-in-practice.
This report is based on the intervention of GenE-HumDi members in front of the Committee for Advanced Therapies (CAT) during the Strategic Review and Learning Meeting held in Paphos, Cyprus on April 19-21. This intervention was convened under the Cypriot presidency. GenE-HumDi aim is bringing together academic researchers, clinical innovators, and regulatory authorities, our delegation presented key breakthroughs and established vital connections to accelerate the journey of safe gene-edited treatments from the lab to patients.
Key highlights presented to the CAT include:
- Advancing Safer, High-Precision Editing: Network researchers showcased state-of-the-art editing technologies designed to significantly lower safety risks. By transitioning from traditional DNA-cutting methods to ultra-precise base editing and DNA break-free epigenome modifications, our teams are opening safer pathways for treating genetic blood disorders (such as thalassemia) and enhancing cell therapies.
- Building a Connected European Research Network: Through funded short-term scientific missions and hands-on training schools, GenE-HumDi is actively democratizing cutting-edge expertise. We are enabling early-career scientists across Europe to share specialized tools, master safety testing pipelines, and collaborate across borders.
- Integrating Regulatory Standards into Early Research: To prevent promising therapies from stalling behind regulatory barriers, our presentations highlighted the importance of teaching young scientists about regulatory compliance, genomic safety profiles, and quality manufacturing from the early stages of project design.
- Forging Direct Pathways with Regulators: Interactive discussions with CAT leadership focused on establishing early-stage support channels, such as EMA briefing sessions. This dialogue ensures academic innovators receive clear guidance long before clinical trials begin.
- Co-Creating Shared Standards and Guidelines: To bridge the gap between scientific discovery and approval, GenE-HumDi and CAT delegates agreed to collaborate on joint consensus papers and involve regulatory experts directly as guest educators in future network training events.
By linking cutting-edge genetic innovation directly with regulatory expertise, GenE-HumDi is helping shape a clearer, safer, and more accessible future for advanced gene therapies across Europe.
Read te Full Report here:
We are thrilled to announce our upcoming Training School on Prime Editing (PE) applications and analysis, hosted at CIEMAT: Centro de investigaciones energéticas medioambientales y tecnológicas, in Madrid (Spain)
Image credit Shuto et al 2024 (Shuto, Y., Nakagawa, R., Zhu, S. et al. Structural basis for pegRNA-guided reverse transcription by a prime editor. Nature 631, 224–231 (2024). https://doi.org/10.1038/s41586-024-07497-8)
WHEN?
SEPTEMBER 1-2
Tuesday September 1st
| 08:30 | Welcome |
| 09:00 | PRIME EDITING – INTRODUCTION AND OVERVIEW Beatriz Olalla |
| 09:20 | PRIME EDITING – HOW DOES IT WORK? Johannes Karl Dohr |
| 10:00 | PRACTICAL SESSION: PEmax mRNA Part I: • Introduction: Steps to perform a Prime editing experiment. • Hands on: In vitro transcription of PEmax mRNA. |
| 12:00 | GUIDE DESIGN TOOLS Sofia Ottonello |
| 12:45 | LUNCH BREAK |
| 14:00 | PRACTICAL SESSION: PEmax mRNA Part II: • Hands on: DNAse treatment • Hands on: Poly(A) tail addition |
| 15:00 | PRACTICAL SESSION: PegRNA and sgRNA design Sofia Ottonello |
| 16:00 | PRACTICAL SESSION: PEmax mRNA Part III: • Hands on: mRNA purification • Hands on: mRNA quantification • Hands on: mRNA quality Control – Qubit quantification |
| 18:00 | Questions & Answers |
| 20:00 | Networking event |
Wednesday September 2nd
| 09:00 | PRIME EDITING APPLICATIONS: • Epidermolysis Bullosa – Alex Bassons • Fanconi anemia – Beatriz Olalla • Cardiomyopathies – Johannes Karl Dohr & Sofia Ottonello |
| 11:00 | PRACTICAL SESSION: PE system nucleofection: – Introduction: Experimental workflow: From electroporation to PCR analysis • Hands on: Nucleofection in suspension cells • Hands on: Nucleofection in adherent cells |
| 14:00 | LUNCH BREAK |
| 15:30 | PRIME EDITING SAFETY: OFF-TARGET ACTIVITY Sergio López |
| 16:00 | PRACTICAL SESSION: • Introduction: Next steps and data analysis • Hands on: CRISPResso analysis |
| 17:30 | Questions & Answers Adjourn |
Application & Funding
GenE-HumDi courses are open to all EU members and Near Neighbour Countries, with a particular focus on promoting the participation of Inclusiveness Target Countries and encouraging Early career scientist.
- Cost: Selected attendees are enrolled free of charge.
- Limited Capacity: Seats are strictly limited to ensure high levels of interaction between trainers and trainees.
- Funding: A call is now open to provide financial support for travel costs and daily allowances for selected participants, in accordance with COST guidelines.
A call is opened to provide funding for selected participants, to cover Travel costs and Daily Allowances, in accordance with the COST guidelines https://www.cost.eu/uploads/2025/11/COST-094-21-Annotated-Rules-for-COST-Actions-Level-C-V3.0-25-IX-2025.pdf
Important Considerations
July 15th UPDATE
Applications are no longer admitted .Applicants need to send the form bellow to raquel.soriano@juntadeandalucia.es
These forms will be used to shortlist applicants in case they exceed the seats available.
Granada, June 23, 2026
We are thrilled to announce our upcoming Training School on Homology-Directed Repair (HDR) and Adeno-Associated Virus (AAV) Based Delivery Technologies, hosted at the Kavli Institute for Systems Neuroscience in Trondheim, Norway.
June 24th -26th,
write it down now!!
This 3-day intensive course is designed for researchers and professionals looking to master precise DNA repair mechanisms and cutting-edge gene delivery platforms. Participants will explore the theoretical foundations of genomic integrity and gain practical insights into leveraging these pathways for accurate gene editing applications, specially addressed towards therapeutic use.
The training is structured into three thematic days, each led by distinguished experts in the field:
June 24th:
T Cells In Vitro Gene Editing & HDR Strategies
- Focus: Molecular mechanisms of HDR, designing HDR experiments for CAR-T cell therapies, and drug modulation to enhance repair efficiency.
- Confirmed Speakers & Organizers: Karim Benabdellah, Alessia Cavazza, and Erden Atilla.
June 25th:
Hematopoietic Stem Cells (HSCs), In Vivo Gene Editing & Metabolic Diseases
- Focus: HSC biology, HDR strategies for in vivo editing, and clinical approaches for treating metabolic diseases through genomic modification.
- Confirmed Speakers & Organizers: Gloria Gonzalez-Aseguinolaza and Jose-Carlos Segovia
June 26th:
AAV-Based Delivery of Gene-Editing Components
- Focus: AAV production strategies (iodixanol gradient vs. affinity chromatography), cell-type specific delivery, and qPCR-based vector titration.
- Confirmed Speakers & Organizers: Rajeevkumar Raveendran Nair, Dr. Sofie Snipstad, and Petter Anderse
Training overview
This course offers an in-depth overview of Homology-Directed Repair (HDR) and homologous recombination, two fundamental cellular mechanisms for precise DNA repair and genome engineering. The training will take place June 24th to June 26th, and is designed for researchers, students, and professionals interested in understanding how these pathways maintain genomic integrity and how they can be leveraged for accurate gene editing applications. The program will cover the molecular mechanisms underlying HDR and homologous recombination, with a particular focus on their use in CRISPR/Cas-based genome editing strategies. Participants will explore real-world case studies and experimental approaches aimed at achieving precise genetic modifications through HDR. The training school will focus as well on adeno-associated virus (AAV) delivery vectors and their applications in gene editing, together with an overview of current production platforms for research. Key purification approaches, including iodixanol gradient ultracentrifugation and affinity chromatography, will be discussed, with emphasis on the critical steps involved in these techniques. The program will also cover vector titration using quantitative PCR (qPCR) and the interpretation of resulting data.
In addition, the course will address current challenges and limitations associated with HDR-based editing, including efficiency and cell-cycle dependence, as well as emerging strategies to enhance HDR outcomes. Alternative DNA repair pathways, such as Non-Homologous End Joining (NHEJ) and base editing technologies, will also be discussed to provide a comprehensive perspective on genome editing approaches. By the end of the course, participants will have gained both theoretical insights and practical guidance to apply, HDR, homologous recombination, and AAV production techniques, effectively in their own research projects.
Main Objectives
- To provide a comprehensive understanding of the molecular mechanisms underlying Homology-Directed Repair (HDR) and homologous recombination.
- To explain the role of HDR and homologous recombination in maintaining genomic integrity and enabling precise genome editing.
- To explore how HDR pathways can be harnessed for accurate genetic modifications using CRISPR/Cas-based technologies.
- To analyze the limitations and challenges associated with HDR-mediated genome editing and discuss strategies to enhance editing efficiency.
- To compare HDR with alternative DNA repair and genome editing pathways, including Non-Homologous End Joining (NHEJ) and base editing.
- To equip participants with practical knowledge and experimental design skills to apply HDR-based genome editing approaches in their own research projects.
- To understand Adeno-associated virus (AAV) delivery vectors and their applications in gene editing.
- To discuss critical steps involved in iodixanol-based purification compared to chromatography-based methods.
- To demonstrate vector titration using quantitative PCR (qPCR) and interpretation of resulting data.
Expected Outputs
- ● Participants will gain a solid theoretical understanding of Homology-Directed Repair (HDR) and homologous recombination mechanisms.
- ● Participants will be able to design and plan genome editing experiments that utilize HDR pathways for precise genetic modifications.
- ● Participants will acquire practical experience in laboratory techniques for HDR-based genome editing and in the bioinformatics analysis of the recombination outcome
- ● Participants will be able to critically evaluate the limitations and efficiency of HDR in different experimental contexts and propose strategies to overcome them.
- ● Participants will understand and compare alternative DNA repair and genome editing pathways, including NHEJ and base editing, and their applications.
- ● Participants will be equipped to apply HDR and homologous recombination knowledge to their own research projects, enhancing experimental design and outcome predictability.
- ● Participants will acquire knowledge on adeno-associated virus (AAV) delivery vectors and their applications in gene editing, alongside an overview of current research production platforms.
- ● Participants will understand the key purification approaches, including iodixanol gradient ultracentrifugation and affinity chromatography, as well as vector titration by qPCR, with emphasis on critical methodological steps
Application & Funding
GenE-HumDi courses are open to all EU members and Near Neighbour Countries, with a particular focus on promoting the participation of Inclusiveness Target Countries and encouraging Early career scientist.
- Cost: Selected attendees are enrolled free of charge.
- Limited Capacity: Seats are strictly limited to ensure high levels of interaction between trainers and trainees.
- Funding: A call is now open to provide financial support for travel costs and daily allowances for selected participants, in accordance with COST guidelines.
A call is opened to provide funding for selected participants, to cover Travel costs and Daily Allowances, in accordance with the COST guidelines https://www.cost.eu/uploads/2025/11/COST-094-21-Annotated-Rules-for-COST-Actions-Level-C-V3.0-25-IX-2025.pdf
IMPORTANT CONSIDERATIONS
Only applications received before May10th will be considered for Funding.
Applicants need to send the form bellow to raquel.soriano@juntadeandalucía.es
These forms will be used to shortlist applicants in case they exceed the seats available.
Further details on the calendar and contents will be disclosed shortly. Please check regularly our media for updates.
🌟 GenE-HumDi Coordinated CRISPRMED26 Workshops! 🌟
Dear GenE-HumDi Members,
We support early career and young researchers in the field of therapeutic Gene Editing. For this reason, we are very excited to announce that we will be supporting selected young members attending the CRISPRMED26 Conference and enrolled in the CRISPRMED26 Workshops, co-organized by GenE-HumDi (COST action CA21113) and CRISPR MEDICINE NEWS (CRISPRMED) as part of the CRISPRMED’26 conference.
The CRISPRMED26 workshops offer students an interactive opportunity to acquire critical applied knowledge and skills that will expand their profile in the gene-editing field. With a limited number of 30 places per workshop, we focus on delivering high-quality, interactive workshops in which you can learn by doing instead of just listening.
📚 Workshop Topics And FacilitATors
Tools: Choosing the Right Gene-Editing Approach
Dr. Claudio Mussolino, (Universitaetsklinikum Freiburg. Germany)
Dr. Raúl Perez-Jimenez, (Ikerbasque Research Professor. Spain)
Dr. Antonio Carusillo, (Università di Modena e Reggio Emilia. Italy)
The workshop will start with an introduction to various genome-editing technologies highlighting their mechanisms, advantages, and limitations.
We will also discuss recent developments in genome-editing tools, focusing on those DSB-free and with demonstrated therapeutic potential, such as base- and prime editing. Next, we will cover criteria for selecting the appropriate genome-editing tool based on the targeted disease and present case studies of therapeutic applications.
We will emphasise that different diseases require distinct genome-editing strategies depending on the aim, such as gene replacement, gene restoration, or gene insertion.
The workshop will include a hands-on session with practical demonstrations and group activities to design genome-editing experiments. Finally, we will address ethical and safety considerations, emphasising regulatory guidelines and best practices.
The workshop will be highly interactive, with Q&A sessions throughout, pausing at key points for discussion.
Delivery: Navigating the CRISPR Delivery Landscape
Dr. Juan Antonio Marchal, (University of Granada.Spain)
Dr. André Görgens, (Karolinska Institutet | Department of Laboratory Medicine, Division of Biomolecular and Cellular Medicine. Sweden)
This workshop will focus on navigating the current landscape of viral- and non-viral delivery methods for CRISPR gene-editing tools.
The session will provide the participants a broad and comparative introduction on the various delivery methods available for the different CRSPR gene-editing tools, their advantages and disadvantages.
Importantly, the workshop will try to achieve a comprehensive understanding on how to select the right delivery tool for a specific CRISPR gene editing in cells to achieve high efficacy, the so-called “CRISPR-Delivery-Cell, CDC” match-making procedure.
Safety: Pre-clinical Safety Analyses
Dr. Ciaran Lee PhD (University College Cork. Ireland)
This workshop will focus on the side effects derived from the use of genome editors. The session will address the risks associated with the unspecific activity of CRISPR-based platforms, which can impact both the safety and efficacy of gene-editing approaches. Participants will gain a comprehensive understanding of the different types of potential genotoxic events and of the different methods available to monitor unintended genomic modifications, including those aligned with regulatory guidelines:
– Off-target activity of genome editors
– Genotoxicity: on- and off-target aberrations
– Off-target evaluation methods
– Mitigation strategies
– Hands-on basic training on specificity prediction
📝 SuCCESS
Close to a hundred young researchers and experts participated of these workshops to update and bring cutting edge genome editing. Researchers highlighted the possibilities and capabilities of state of the art technologies and also put their performance on the spotlight to realize the need for detailed selection on genome editing tools and delivery strategies and current limitations predicting safety based solely on bio models.
Picture Credits : Karim Bebadellah .Copenhagen, April 14th 2026
Picture Credits : Karim Bebadellah .Copenhagen, April 14th 2026
Dear GenE-HumDi Members,
The GenE-HumDi COST Action organized the CRISPRMED26 Satellite Meeting “Access, IP Landscape and FTO“ in Copenhagen.
The coordinated panel sessions on Access, IP Landscape, and FTO, which culminated in a high-level Panel Discussion participated by GenE-HumDi experts Meliha Negin and Leonardo Martin. This has been a unique opportunity to engage with the world’s leading experts in gene editing law, patenting, and clinical regulation
🗺️ Access, IP Landscape and FTO
In Copenhagen, during the CRISPRMED26 Satellite Sessions on April 13th, we are deep diving into the legal hurdles of gene editing with global experts including Ulrich Storz, Franziska Bächler, Jacob S. Sherkow, Timo Minssen, and Kevin E. Noonan
The GenE-HumDi Panel: The afternoon concludes with a cross-disciplinary panel discussion featuring Meliha Negin and Leonardo Martin, bridging the gap between scientific innovation, patent protection, and regulatory approval.
📚Panel Discussion
The discussion panel was participated by experts and members interested in Gene Editing Patent(s) and IP. After the Satellite Session a working panel discussed freedom to operate in the genome editing field and protection of intellectual property¡, which is key to gain interest of mayor market stakeholders to become involved and secure commercial distribution of Medical advances.
Event Pictures
Photograph credits:
Raquel Soriano, Copenhagen, April 13th, 2026
(Updated April 15th)
Call for Action Ambassadors: Represent GenE-Humdi on the Global Stage.
Deadline Extended!
The GenE-Humdi COST Action (CA21113) is looking for dedicated members to serve as the voice of our network at major international scientific forums
This Conference Grant is specifically designed for researchers who will present our collective milestones, activities, and results.
The Mission: Visibility & Impact
The primary goal of this grant is the strategic promotion of the GenE-Humdi Action. We are seeking presenters who can:
- Increase the visibility of CA21113 within the research community.
- Disseminate GenE-Humdi results to high-profile end-users and regulatory stakeholders.
- Attract new participants and stakeholders to our network.
What We Support
We provide up to 2,500 € for in-person attendance at conferences where the grantee will deliver an oral presentation featuring the GenE-Humdi COST Action. * (Actual fund is decided based on the information provided in the application).
Selection is heavily weighted toward how well the presentation aligns with the Action’s strategic priorities and its contribution to our collective dissemination goals.
How to Apply Applicants must demonstrate a clear commitment to increasing the visibility of CA21113.
- Deadline: April 6th.
- Process: Submit via the e-COST management tool.
- Requirements: Include an acceptance letter and a commitment letter justifying how your participation promotes the Action.
- For More info read the DCG in full:
🌟 Call for attendees to the CRISPRMED26 Satellite Meetings! 🌟
Dear GenE-HumDi Members,
The GenE-HumDi COST Action is pleased to announce a call for Travel Grants to support the participation of young researchers and industry professionals in the upcoming CRISPRMED26 Satellite Meeting “Access, IP Landscape and FTO“ in Copenhagen.
This call specifically targets those attending the coordinated panel sessions on Access, IP Landscape, and FTO, which will culminate in a high-level Panel Discussion participated by GenE-HumDi experts Meliha Negin and Leonardo Martin. This is a unique opportunity to engage with the world’s leading experts in gene editing law, patenting, and clinical regulation
🗺️ Access, IP Landscape and FTO
In Copenhagen, during the CRISPRMED26 Satellite Sessions on April 13th, we are deep diving into the legal hurdles of gene editing with global experts including Ulrich Storz, Franziska Bächler, Jacob S. Sherkow, Timo Minssen, and Kevin E. Noonan
The GenE-HumDi Panel: The afternoon concludes with a cross-disciplinary panel discussion featuring Meliha Negin and Leonardo Martin, bridging the gap between scientific innovation, patent protection, and regulatory approval.
📚 Who can apply?
We are considering:
- Young Researchers: PhD students, Post-docs, Junior PI (40 years old or younger).
- Industry Members: Professionals from SMEs or the pharmaceutical sector related to Gene Editing Therapies (40 years old or younger).
- Applicants must be affiliated to GenE-HumDi COST Action to be able to submit the applications ( need access through : https://e-services.cost.eu/). Funding is open to all COST Action members, but active members a within the network are encouraged to apply.
💶What does the grant cover?
- Long-distance travel support to/from the venue*
- Daily allowance for the day of the Satellite meeting plus the corresponding part of the days required for travel*
*Long-distance travel expenses and daily allowance will be reimbursed according to the approved budget and will abide by current COST annotated rules.
📝 How to Apply:
Interested attendees must apply soon:
- Send an email to the Grant Holder Manager (raquel.soriano@juntadeandalucia.es)
Please, kindly provide information about the state of your application for the Satellite Meetings. - Include in the email a letter of interest, of about 1,000 words addressed to the Grant Awarding Coordinator. Please include:
- A contact e-mail address (if different from your COST contact).
- Your current position.
- Whether you are an active member in any GeneHumdi WG.
- List your contributions to GeneHumdi initiatives (meetings, white papers, peer-reviewed papers, etc, …)
- How attending will benefit their current position or future perspectives?
- How does your work/research/interest align with the satellite topic ” Access, IP Landscape and FTO“. PLease, mention your:
- Gene Editing Patent(s) developed: Provide the Patent Title(s) and descriptive keywords (ensure no confidential or unpublished information is disclosed)
- Patent Status: (e.g., Filed, Pending, or Granted).
- IP Experience: A brief summary of your previous experience with Intellectual Property or the patenting process.
📅 Deadline:
Applications will be considered from January 19th and
no later than February 28th!
This date is needed to allow the timely resolution and communication of grants on time for the participants to arrange their itineraries to/from the venue.
The budget is limited and active young members not previously selected for funded participation in GeneHumdi calls will be given priority. COST YRIs having and oral communication already accepted by the CRISPR MEDICINE 26 conference will be positively considered during the application evaluation.
The Grant Award Coordinator will ensure fair review of all applications and shortlisted applicants are expected to receive feedback by the second week of March.
📚 Call Documentation:
Don’t miss this opportunity to enhance your knowledge and network with experts in the field!
For questions or to submit your application, contact the Grant Holder Manager at raquel.soriano@juntadeandalucia.es.
We look forward to your applications!
Best regards,
The GenE-HumDi Team
Granada, February 19th, 2026
(Updated April 1st)
On February 11, we celebrate the Women and girls in Science and Technology, #Women in science.
For the past 3 years we feature successful female leaders from our COST Action CA21113. As they are inspiration for younger scientist.
This year we feature on of our youngest @genehumdi members : María Ortiz who is developing advanced genome editing tools for immunotherapy in Granada. She borrow a fierce quote from Nobel Laureate Barbara McClintock:
GenE-HumDi encourages and support girls and young female researchers to pursue the dream of Using Genome Editing for the treatment of Huma Diseases by offering support and a network of peers to boost their research through collaborative training and research.
Previous Inspirational quotes:
#WomenInScience 2025 inspirational quote was favourite of Dr. Carla Fuster. Leader expert in Genome Editing off-target evaluation and genotoxicity. Her inspirational choice, coined by professor Lynn Margulis, can´t get any better alignment with our COST Action principles.
#WomenInScience 2024 featured a inspirational quote from Nobel Laureate Rita Levi Montalcini, favourite of Annarita Miccio a world class Scientist Researching genome Editing to boost therapeutic approaches for hematologic genetic disorders.
#WomenInScience 2023 opened with a quote hand picked by our COST action Chair Alexia Cavazza. She was inspired by pioneer Afro American Astronaut Mae Jemison encouraging curiosity, which is universally accepted to be the fuel of good research.
This post seek to Acknowledge all women in GeneHumdi COST Action. As they stand as true references and inspiration for young scientist and because, this COST Action would not be possible without their talent and commitment.
